Streamlining Prior Authorization Reforms: Impacts and Insights for HEOR

By Rene Pretorius

June 30, 2025

prior authorization reforms

Summary
The U.S. Department of Health and Human Services (HHS) announced a collaboration with major insurers to streamline prior authorization reforms for Medicare Advantage, Medicaid, and commercial plans. The initiative targets standardized electronic submissions by 2027. It also aims to reduce prior authorization requirements by 2026. The goal is to accelerate care decisions and minimize delays through real-time approvals and clinician-reviewed denials. Participating insurers, covering 257 million Americans, pledged to honor existing authorizations during coverage transitions. They also committed to improving communication during appeals.

Key Insights
The reforms prioritize six core commitments. These include electronic standardization via FHIR-based APIs and reduced prior authorization volumes by 2026. Other commitments are continuity of care during plan transitions, improved transparency, real-time approvals by 2027, and clinician oversight of denials. This effort aligns with CMS’s Interoperability and Prior Authorization rule. It addresses systemic barriers that delay care despite medical necessity. Notably, bipartisan congressional support underscores the urgency of these reforms. Physicians continue to cite prior authorization as a major obstacle to timely treatment.

Background Context
Prior authorization has long been criticized for creating administrative burdens and care delays. A reported 94% of physicians say it leads to treatment delays. Additionally, 80% note patient abandonment of necessary care. The initiative builds on CMS’s existing regulatory framework. It seeks to reduce redundancy and leverage interoperability standards for seamless electronic submissions. Reputable sources, such as the American Medical Association, have documented the negative impacts of prior authorization.

Implications for HEOR
The prior authorization reforms could significantly reduce administrative costs for providers and payors. Standardizing electronic submissions and minimizing redundant requests may help. Faster approvals could enhance health outcomes by reducing delays in critical diagnostics and procedures. Real-time responses and FHIR standardization may improve data interoperability. This could enable more robust cost-effectiveness analyses and reduce care access disparities. However, success depends on insurer compliance and CMS’s enforcement capacity.

In the long term, these changes may lead to cost savings from reduced administrative overhead. They could also improve resource allocation in high-value care areas. Additionally, they may support HEOR research by providing standardized datasets. While the initiative addresses inefficiencies, challenges remain in tackling systemic inequities. For more information, refer to the detailed source here.

Reference url

Recent Posts

global instability generic pharmaceutical sustainability
Global Instability Impacting Generic Pharmaceutical Sustainability in Portugal

By João L. Carapinha

July 8, 2026

Global instability impacting generic pharmaceutical sustainability has become a pressing challenge for Portugal, where rising international conflicts are undermining the economic viability of generic drug production. After 34 years of ensuring affordable access to essential treatments, these medi...
omaveloxolone appropriate utilization consensus
Omaveloxolone Appropriate Utilization Consensus Framework for Friedreich Ataxia

By João L. Carapinha

July 8, 2026

The omaveloxolone appropriate utilization consensus delivers a tightly controlled framework for using Skyclarys in Friedreich’s ataxia, restricting initiation and discontinuation decisions to two specialized Dutch centers. By combining validated functional scales with strict safety thresholds and...
biologic dispensing implementation gaps
Biologic Dispensing Implementation Gaps Challenge Patient Access to Care

By João L. Carapinha

July 7, 2026

Biologic dispensing implementation gaps are undermining equitable access to advanced therapies for inflammatory bowel disease across Portugal’s public hospitals. Despite clear legislative changes, institutions continue to reject prescriptions for biologics written by private specialists, forcing ...